A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Neoplasms, Breast
Interventions: DRUG: Lapatinib|BIOLOGICAL: Trastuzumab|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: Vinorelbine
Sponsor: GlaxoSmithKline